NAMSA’s latest white paper, Joining Preclinical and Clinical Development: A Practical Approach to Reducing Medical Device Timelines, details the benefits of working with an organization who has the capabilities to conduct both Preclinical and Clinical programs in-house as opposed to utilizing multiple organizations for these purposes. NAMSA, the global medical research organization (MRO), believes there is additional success to be had by focusing on the intersection of adjacent development steps, and by combining multiple steps or portions of the product development lifecycle into a more streamlined model.
With our Preclinical and Clinical capabilities and experts, combined with our Regulatory expertise, we have the potential to involve our Clinical and Regulatory experts in the Preclinical stage of the medical device development. Thus, allowing our experts to follow the development path every step of the way, providing them with the knowledge they need early on to successfully guide the medical device to market. By including these experts early in the process, NAMSA can not only save a client time (potentially anywhere from 4 to 6 months in their total development cycle), but can also prepare a device manufacturer for possible delays or issues that may occur in the Clinical stage.